




Instance: composition-en-69ba7123d300a992a466115b331a7218
InstanceOf: CompositionUvEpi
Title: "Composition for oslif Package Leaflet"
Description:  "Composition for oslif Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp69ba7123d300a992a466115b331a7218)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - oslif"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet:</p>
<ol>
<li>What Oslif Breezhaler is and what it is used for </li>
<li>What you need to know before you use Oslif Breezhaler </li>
<li>How to use Oslif Breezhaler </li>
<li>Possible side effects </li>
<li>How to store Oslif Breezhaler </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What oslif is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What oslif is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Oslif Breezhaler is 
Oslif Breezhaler contains the active substance indacaterol which belongs to a group of medicines 
called bronchodilators. When you inhale it, it relaxes the muscles in the walls of the small air passages 
in the lungs. This helps open up the airways, making it easier to get air in and out. </p>
<p>What Oslif Breezhaler is used for 
Oslif Breezhaler is used to make breathing easier for adult patients who have breathing difficulties due 
to a lung disease called chronic obstructive pulmonary disease (COPD). In COPD the muscles around 
the airways tighten. This makes breathing difficult. This medicine relaxes these muscles in the lungs, 
making it easier for air to get in and out of the lungs. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take oslif"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take oslif"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not use Oslif Breezhaler 
- if you are allergic to indacaterol or any of the other ingredients of this medicine (listed in 
section 6). </p>
<p>Warnings and precautions 
Talk to your doctor or pharmacist before using Oslif Breezhaler </p>
<p>if you have asthma (in this case you should not use Oslif Breezhaler). </p>
<p>if you have heart problems. </p>
<p>if you have epilepsy. </p>
<p>if you have thyroid gland problems (thyrotoxicosis). </p>
<p>if you have diabetes. </p>
<p>During treatment with Oslif Breezhaler, </p>
<p>Stop using the medicine and tell your doctor immediately if you get tightness of the chest, 
coughing, wheezing or breathlessness immediately after using the medicine. These may be signs 
of a condition called bronchospasm. </p>
<p>Tell your doctor immediately if your COPD symptoms (breathlessness, wheezing, cough) do 
not improve or get worse. </p>
<p>Children and adolescents 
Oslif Breezhaler should not be given to children or adolescents below the age of 18 years </p>
<p>Other medicines and Oslif Breezhaler 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. 
In particular, please tell your doctor if you are using: </p>
<p>medicines for breathing problems that are similar to Oslif Breezhaler (i.e. medicines such as 
salmeterol and formoterol). You may be more likely to get side effects. </p>
<p>medicines called beta blockers that are used for high blood pressure or other heart problems 
(such as propranolol), or for the eye problem called glaucoma (such as timolol). </p>
<p>medicines that lower the amount of potassium in your blood. These include: * 
steroids (e.g. prednisolone), * 
diuretics (water tablets) used for high blood pressure such as hydrochlorothiazide, * 
medicines for breathing problems such as theophylline. </p>
<p>Pregnancy and breast-feeding 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor or pharmacist for advice before using this medicine.  </p>
<p>You should not use Oslif Breezhaler unless your doctor tells you so. </p>
<p>Ask your doctor or pharmacist for advice before taking any medicine. </p>
<p>Driving and using machines 
It is unlikely that Oslif Breezhaler will affect your ability to drive and use machines. </p>
<p>Oslif Breezhaler contains lactose 
This medicine contains lactose (milk sugar). If you have been told by your doctor that you have an 
intolerance to some sugars, contact your doctor before using this medicine. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take oslif"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take oslif"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if 
you are not sure. </p>
<p>How much Oslif Breezhaler to use </p>
<p>The usual dose is to inhale the content of one capsule each day. Your doctor may tell you to use 
the 150 microgram capsule or the 300 microgram capsule depending on your condition and on 
how you respond to the treatment. Do not use more than your doctor tells you to use. </p>
<p>Use your inhaler at the same time each day, the effects last for 24 hours. This ensures that there 
is always enough medicine in your body to help you breathe more easily throughout the day and 
night. It will also help you to remember to use it. </p>
<p>How to use Oslif Breezhaler </p>
<p>In this pack, you will find an inhaler and capsules (in blister) that contain the medicine as 
inhalation powder. The Oslif Breezhaler inhaler enables you to inhale the medicine contained in 
a capsule. </p>
<p>Only use the capsules with the inhaler provided in this pack (Oslif Breezhaler inhaler). The 
capsules should remain in the blister until you need to use them. </p>
<p>When you start a new pack, use the new Oslif Breezhaler inhaler that is supplied in the pack. </p>
<p>Dispose of each inhaler after 30 days of use. </p>
<p>Do not swallow the capsules. </p>
<p>Please read the instructions at the end of this leaflet for more information about how to 
use the inhaler. </p>
<p>If you use more Oslif Breezhaler than you should 
If you have inhaled too much Oslif Breezhaler or if someone else uses your capsules, tell your doctor 
immediately or go to the nearest emergency unit. Show the pack of Oslif Breezhaler. Medical attention 
may be needed. You may notice that your heart is beating faster than usual, or you may have a 
headache, feel drowsy, feel nauseous or have to vomit. </p>
<p>If you forget to use Oslif Breezhaler 
If you forget to inhale a dose, inhale just one dose at the usual time the next day. Do not inhale a 
double dose to make up for a forgotten dose. </p>
<p>How long to continue your treatment with Oslif Breezhaler </p>
<p>Keep using your treatment with Oslif Breezhaler for as long as your doctor tells you. </p>
<p>COPD is a long-term disease and you should use Oslif Breezhaler every day and not only when 
you have breathing problems or other symptoms of COPD. 
If you have questions about how long to continue your treatment with Oslif Breezhaler, talk to your 
doctor or pharmacist. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Some side effects may be serious. Tell your doctor immediately </p>
<p>if you get crushing chest pain, (common). </p>
<p>if you get high levels of sugar in your blood (diabetes). You will feel tired, very thirsty and 
hungry (without gaining weight) and will pass more urine than usual (common). </p>
<p>if you get irregular heart beat (uncommon). </p>
<p>if you get symptoms of an allergic reaction such as rash, itching, hives, difficulty breathing or 
swallowing, dizziness (uncommon). </p>
<p>if you have difficulty breathing with wheezing or coughing (uncommon). </p>
<p>Other side effects may include: </p>
<p>Very common side effects (may affect more than 1 in 10 people) </p>
<p>cold-like symptoms. You may get all or most of the following: sore throat, runny nose, blocked 
nose, sneezing, coughing, headache. </p>
<p>Common side effects (may affect up to 1 in 10 people) </p>
<p>feeling of pressure or pain in the cheeks and forehead (inflammation of the sinuses) </p>
<p>runny nose </p>
<p>cough </p>
<p>sore throat </p>
<p>headache </p>
<p>dizziness </p>
<p>palpitations </p>
<p>muscle spasm </p>
<p>swollen hands, ankles and feet (oedema) </p>
<p>itching/rash </p>
<p>chest pain </p>
<p>pain in muscles, bones or joints </p>
<p>Uncommon side effects (may affect up to 1 in 100 people) </p>
<p>fast heart beat </p>
<p>tingling or numbness </p>
<p>muscle pain </p>
<p>Some people occasionally cough soon after inhaling the medicine. Cough is a common symptom in 
COPD. If you experience coughing briefly after inhaling the medicine, do not worry. Check your 
inhaler to see if the capsule is empty and that you have received the full dose. If the capsule is empty, 
there is no need for concern. If the capsule is not empty then inhale again as directed. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects you can help provide more information on the 
safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store oslif"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store oslif"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. 
Do not use this medicine after the expiry date which is stated on the carton and blister after  EXP . 
The expiry date refers to the last day of that month. 
Do not store above 30 C. 
Store in the original package in order to protect from moisture and do not remove until immediately 
before use. 
Do not use this medicine if you notice that the pack is damaged or show signs of tampering. 
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Oslif Breezhaler contains 
- Each Oslif Breezhaler 150 microgram capsule contains 150 microgram indacaterol as 
indacaterol maleate. The other ingredients include lactose and the capsule is made of gelatin. 
- Each Oslif Breezhaler 300 microgram capsule contains 300 microgram indacaterol as 
indacaterol maleate. The other ingredients include lactose and the capsule is made of gelatin. </p>
<p>What Oslif Breezhaler looks like and content of the pack 
In this pack, you will find an inhaler, together with capsules in blister. The capsules are transparent 
(uncoloured) and contain a white powder. </p>
<p>Oslif Breezhaler 150 microgram capsules have a black product code  IDL 150  printed above a 
black bar and a black company logo (
) printed below the black bar. </p>
<p>Oslif Breezhaler 300 microgram capsules have a blue product code  IDL 300  printed above a 
blue bar and a blue company logo (
) printed below the blue bar. </p>
<p>The following pack sizes are available: 
Carton containing 10 capsules and 1 inhaler. 
Carton containing 30 capsules and 1 inhaler. 
Multipack comprising 2 packs (each containing 30 capsules and 1 inhaler). 
Multipack comprising 3 packs (each containing 30 capsules and 1 inhaler). 
Multipack comprising 30 packs (each containing 10 capsules and 1 inhaler). </p>
<p>Not all pack sizes or strengths may be available in your country. </p>
<p>Marketing Authorisation Holder 
Novartis Europharm Limited 
Vista Building 
Elm Park, Merrion Road 
Dublin 4 
Ireland </p>
<p>Manufacturer 
Novartis Pharma GmbH 
Roonstra e D-90429 Nuremberg 
Germany </p>
<p>Novartis Farmac utica SA 
Gran Via de les Corts Catalanes, 08013 Barcelona 
Spain </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Novartis Pharma N.V. 
T l/Tel: +32 2 246 16 Lietuva 
SIA Novartis Baltics Lietuvos filialas 
Tel: +370 5 269 16 <br />
Novartis Bulgaria EOOD 
 .: +359 2 489 98 Luxembourg/Luxemburg 
Novartis Pharma N.V. 
T l/Tel: +32 2 246 16  esk  republika 
Novartis s.r.o. 
Tel: +420 225 775 Magyarorsz g 
Novartis Hung ria Kft. 
Tel.: +36 1 457 65 Danmark 
Novartis Healthcare A/S 
Tlf: +45 39 16 84 Malta 
Novartis Pharma Services Inc. 
Tel: +356 2122 2Deutschland 
Novartis Pharma GmbH 
Tel: +49 911 273 0 </p>
<p>Nederland 
Novartis Pharma B.V. 
Tel: +31 88 04 52 Eesti 
SIA Novartis Baltics Eesti filiaal 
Tel: +372 66 30 Norge 
Novartis Norge AS 
Tlf: +47 23 05 20 <br />
Novartis (Hellas) A.E.B.E. 
 : +30 210 281 17  sterreich 
Novartis Pharma GmbH 
Tel: +43 1 86 6Espa a 
Ferrer Internacional, S.A. 
Tel: +34 93 600 37 Polska 
Novartis Poland Sp. z o.o. 
Tel.: +48 22 375 4France 
Pierre Fabre M dicament 
T l: +33 1 49 10 96 Portugal 
Laborat rio Medinfar - Produtos Farmac uticos, 
S.A. 
Tel: +351 21 499 7Hrvatska 
Novartis Hrvatska d.o.o. 
Tel. +385 1 6274 Rom nia 
Novartis Pharma Services Romania SRL 
Tel: +40 21 31299 Ireland 
Novartis Ireland Limited 
Tel: +353 1 260 12 Slovenija 
Novartis Pharma Services Inc. 
Tel: +386 1 300 75  sland 
Vistor hf. 
S mi: +354 535 7Slovensk  republika 
Novartis Slovakia s.r.o. 
Tel: +421 2 5542 5Italia 
Novartis Farma S.p.A. 
Tel: +39 02 96 54 1 
Suomi/Finland 
Novartis Finland Oy 
Puh/Tel: +358 (0)10 6133 <br />
Novartis Pharma Services Inc. 
 : +357 22 690 Sverige 
Novartis Sverige AB 
Tel: +46 8 732 32 Latvija 
SIA Novartis Baltics 
Tel: +371 67 887 United Kingdom (Northern Ireland) 
Novartis Ireland Limited 
Tel: +44 1276 698This leaflet was last revised in </p>
<p>Other sources of information 
Detailed information on this medicine is available on the European Medicines Agency website: 
http://www.ema.europa.eu 
INSTRUCTIONS FOR USE OF OSLIF BREEZHALER INHALER </p>
<p>Please read the full Instructions for Use before using the Oslif Breezhaler. </p>
<p>Insert 
Pierce and release 
Inhale deeply 
Check capsule is empty </p>
<p>Step 1a: 
Pull off cap 
Step 2a: 
Pierce capsule once 
Hold the inhaler upright. 
Pierce capsule by firmly 
pressing both side 
buttons at the same time. 
Step 3a: 
Breathe out fully 
Do not blow into the 
inhaler. 
Check capsule is empty 
Open the inhaler to see if 
any powder is left in the 
capsule. </p>
<p>You should hear a noise 
as the capsule is pierced. 
Only pierce the capsule 
once. </p>
<p>If there is powder left in 
the capsule: </p>
<p>Close the inhaler. </p>
<p>Repeat steps 3a to 3c. 
Step 1b: 
Open inhaler </p>
<p>Step 2b: 
Release side buttons 
Step 3b: 
Inhale medicine deeply 
Hold the inhaler as 
shown in the picture. 
Place the mouthpiece in 
your mouth and close 
your lips firmly around 
it. 
Do not press the side 
buttons. </p>
<p>Powder 
Empty 
remaining 
1 </p>
<p>2 </p>
<p>3 </p>
<p>Check </p>
<p>Breathe in quickly and as 
deeply as you can. 
During inhalation you 
will hear a whirring 
noise. 
You may taste the 
medicine as you inhale. </p>
<p>Step 1c: 
Remove capsule 
Remove one capsule from 
the blister. 
Do not swallow the 
capsule. </p>
<p>Step 3c: 
Hold breath 
Hold your breath for up 
to 5 seconds. 
Remove empty capsule 
Put the empty capsule in 
your household waste. 
Close the inhaler and 
replace the cap. </p>
<p>Step 1d: 
Insert capsule 
Never place a capsule 
directly into the 
mouthpiece. </p>
<p>Important Information 
  Oslif Breezhaler 
capsules must always be 
stored in the blister card 
and only removed 
immediately before use. 
  Do not swallow the 
capsule. 
  Do not use the Oslif 
Breezhaler capsules with 
any other inhaler. 
  Do not use the Oslif 
Breezhaler inhaler to 
take any other capsule 
medicine. 
  Never place the capsule 
into your mouth or the 
mouthpiece of the 
inhaler. 
  Do not press the side 
buttons more than once. 
  Do not blow into the 
mouthpiece. 
  Do not press the side 
buttons while inhaling 
through the mouthpiece. 
  Do not handle capsules 
with wet hands. 
  Never wash your inhaler 
with water. </p>
<p>Step 1e: 
Close inhaler </p>
<p>Your Oslif Breezhaler Inhaler pack contains: </p>
<p>One Oslif Breezhaler inhaler </p>
<p>One or more blister cards, each containing either 
6 or 10 Oslif Breezhaler capsules to be used in 
the inhaler </p>
<p>Frequently Asked 
Questions </p>
<p>Why didn t the inhaler 
make a noise when I 
inhaled? 
The capsule may be stuck 
in the capsule chamber. If 
this happens, carefully 
loosen the capsule by 
tapping the base of the 
inhaler. Inhale the 
medicine again by 
repeating steps 3a to 3c. </p>
<p>What should I do if there 
is powder left inside the 
capsule? 
You have not received 
enough of your medicine. 
Close the inhaler and 
repeat steps 3a to 3c. </p>
<p>I coughed after inhaling 
  does this matter? 
This may happen. As long 
as the capsule is empty 
you have received enough 
of your medicine. </p>
<p>I felt small pieces of the 
capsule on my tongue <br />
does this matter? 
This can happen. It is not 
harmful. The chances of 
the capsule breaking into 
small pieces will be 
increased if the capsule is 
pierced more than once. 
Cleaning the inhaler 
Wipe the mouthpiece 
inside and outside with a 
clean, dry, lint-free cloth to 
remove any powder 
residue. Keep the inhaler 
dry. Never wash your 
inhaler with water. 
Disposing of the inhaler 
after use 
Each inhaler should be 
disposed of after all 
capsules have been used. 
Ask your pharmacist how 
to dispose of medicines 
and inhalers that are no 
longer required. </p>
<p>Cap 
Mouthpiece 
Blister 
Side 
buttons 
Inhaler 
Inhaler base 
Blister Card 
Capsule 
chamber 
Screen 
Base </p>         </div>"""      



Instance: composition-da-69ba7123d300a992a466115b331a7218
InstanceOf: CompositionUvEpi
Title: "Composition for oslif Package Leaflet"
Description:  "Composition for oslif Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp69ba7123d300a992a466115b331a7218)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - oslif"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen: 
1. Virkning og anvendelse 
2. Det skal du vide, før du begynder at tage Oslif Breezhaler 
3. Sådan skal du tage Oslif Breezhaler 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What oslif is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What oslif is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Virkning 
Oslif Breezhaler indeholder det aktive stof indacaterol, som tilhører en gruppe lægemidler, der kaldes 
bronkodilatorer. Når stoffet inhaleres, afslappes musklerne i væggene i bronkierne (lungernes små 
luftpassager). Dette hjælper med at åbne luftvejene, hvilket gør det nemmere at trække vejret. </p>
<p>Anvendelse 
Oslif Breezhaler bruges til at lette vejrtrækningen hos voksne patienter, som lider af åndedrætsbesvær 
pga. en lungesygdom, som kaldes kronisk obstruktiv lungesygdom (KOL). Ved KOL trækker 
musklerne omkring luftvejene sig sammen. Dette gør det svært at trække vejret. Dette lægemiddel 
afslapper disse muskler i lungerne, hvilket gør det nemmere for luften at komme ind og ud af 
lungerne. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take oslif"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take oslif"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Oslif Breezhaler 
- hvis du er allergisk over for indacaterol eller et af de øvrige indholdsstoffer i Oslif Breezhaler 
(angivet i punkt 6). </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen eller apotekspersonalet, før du tager Oslif Breezhaler 
 
hvis du har astma (hvis dette er tilfældet, må du ikke tage Oslif Breezhaler). 
 
hvis du har hjerteproblemer. 
 
hvis du har epilepsi. 
 
hvis du har problemer med skjoldbruskkirtlen (tyrotoksikose). 
 
hvis du har sukkersyge. </p>
<p>Under behandling med Oslif Breezhaler: 
 
Stop med at tage medicinen og fortæl det øjeblikkeligt til din læge, hvis du oplever trykken 
for brystet, hoste, hvæsen eller åndenød lige efter, du har taget medicinen. Dette kan være tegn 
på en tilstand kaldet bronkospasmer. 
 
Fortæl det øjeblikkeligt til lægen, hvis dine KOL-symptomer (stakåndethed, hvæsen, hoste) 
ikke forbedres eller bliver værre. </p>
<p>Børn og unge 
Oslif Breezhaler må ikke gives til børn eller unge under 18 år. </p>
<p>Brug af anden medicin sammen med Oslif Breezhaler 
Fortæl altid lægen eller apotekspersonalet, hvis du tager anden medicin, for nylig har taget anden 
medicin eller planlægger at tage anden medicin. 
Fortæl det især til lægen, hvis du tager: 
 
medicin mod åndedrætsbesvær, som svarer til Oslif Breezhaler (fx medicin, såsom salmeterol 
og formoterol). Du kan have større risiko for at få bivirkninger. 
 
Medicin, som kaldes betablokkere, som bruges mod for højt blodtryk eller andre 
hjerteproblemer (fx propranolol), eller mod øjensygdommen kaldet grøn stær (glaukom) (fx 
timolol). 
 
medicin, som nedsætter mængden af kalium i blodet. Dette gælder: * 
steroider (fx prednisolon), * 
diuretika (vanddrivende tabletter), som bruges mod for højt blodtryk, såsom 
hydrochlorthiazid, * 
medicin mod åndedrætsbesvær, som fx theofyllin. </p>
<p>Graviditet og amning 
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid skal 
du spørge din læge eller apotekspersonalet til råds, før du tager dette lægemiddel. </p>
<p>Du må ikke tage Oslif Breezhaler, medmindre du har aftalt det med din læge. </p>
<p>Spørg din læge eller apoteket til råds, før du bruger nogen form for medicin. </p>
<p>Trafik- og arbejdssikkerhed 
Det er usandsynligt, at Oslif Breezhaler vil påvirke din evne til at køre bil eller betjene maskiner. </p>
<p>Oslif Breezhaler indeholder lactose 
Dette lægemiddel indeholder lactose. Kontakt lægen, før du tager dette lægemiddel, hvis lægen har 
fortalt dig, at du ikke tåler visse sukkerarter. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take oslif"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take oslif"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er du i tvivl, så spørg lægen eller 
apotekspersonalet. </p>
<p>Så meget Oslif Breezhaler skal du tage 
 
Den sædvanlige dosis er inhalation af indholdet af én kapsel dagligt. Din læge vil fortælle dig, 
om du skal tage kapslen med 150 mikrogram eller kapslen med 300 mikrogram. Det afhænger 
af din sygdoms tilstand, og hvordan du reagerer på behandlingen. Tag ikke mere, end din læge 
har fortalt dig. 
 
Tag din medicin på samme tidspunkt hver dag. Virkningen varer i 24 timer. Dette sikrer, at der 
altid er tilstrækkeligt med medicin i din krop til at hjælpe dig med at trække vejret nemmere i 
løbet af dagen og natten. Det hjælper dig også til at huske at tage medicinen. </p>
<p>Sådan skal du tage Oslif Breezhaler 
 
Denne pakning indeholder en inhalator og kapsler (i blister), som indeholder medicinen i form 
af et inhalationspulver. Oslif Breezhaler-inhalatoren skal du bruge til at inhalere medicinen i 
kapslen. 
 
Brug kun kapslerne sammen med den vedlagte inhalator (Oslif Breezhaler-inhalator). Kapslerne 
skal forblive i blisteren, indtil de skal bruges. 
 
Når du starter på en ny pakning, skal du bruge den nye Oslif Breezhaler-inhalator, som er 
vedlagt pakningen. 
 
Smid hver inhalator ud når alle kapsler er blevet brugt. 
 
Kapslerne må ikke synkes. 
 
Læs brugsanvisningen sidst i denne indlægsseddel for at få yderligere oplysninger om, 
hvordan du bruger inhalatoren. </p>
<p>Hvis du har taget for meget Oslif Breezhaler 
Hvis du har inhaleret for meget Oslif Breezhaler, eller hvis en anden person bruger dine kapsler, skal 
du straks fortælle det til din læge eller henvende dig på den nærmeste skadestue. Vis dem pakningen 
med Oslif Breezhaler. Lægebehandling kan være nødvendig. Du kan opleve, at dit hjerte slår hurtigere 
end normalt, eller du kan få hovedpine, føle dig sløv, have kvalme eller kaste op. </p>
<p>Hvis du har glemt at tage Oslif Breezhaler 
Hvis du glemmer at inhalere en dosis, skal du blot inhalere en dosis til sædvanlig tid næste dag. Du må 
ikke inhalere en dobbeltdosis som erstatning for den glemte dosis. </p>
<p>Så længe skal du fortsætte med Oslif Breezhaler-behandling 
 
Fortsæt med Oslif Breezhaler-behandlingen, så længe din læge siger, at du skal gøre det. 
 
KOL er en langtidssygdom, og du skal bruge Oslif Breezhaler hver dag og ikke blot, når du har 
åndedrætsbesvær eller andre symptomer på KOL. 
Hvis du har spørgsmål om, hvor lang tid du skal fortsætte din behandling med Oslif Breezhaler, skal 
du tale med din læge eller apoteket. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Nogle bivirkninger kan være alvorlige. Kontakt øjeblikkeligt din læge: 
 
hvis du får stærke brystsmerter (almindelig bivirkning). 
 
hvis du får højt indhold af sukker i blodet (sukkersyge). Du føler dig træt, meget tørstig og 
sulten (uden at tage på i vægt) og har hyppigere vandladning end normalt (almindelig 
bivirkning). 
 
hvis du får uregelmæssig hjerterytme (ikke almindelig bivirkning). 
 
hvis du får symptomer på en allergisk reaktion, som fx udslæt, kløe, nældefeber, svært ved at 
trække vejret eller synke, svimmelhed (ikke almindelig bivirkning). 
 
hvis du har besværet vejrtrækning med hvæsen eller hoste (ikke almindelig bivirkning). </p>
<p>Andre bivirkninger omfatter: </p>
<p>Meget almindelige bivirkninger (kan forekomme hos flere end 1 ud af 10 patienter) 
 
forkølelseslignende symptomer. Du kan få alle eller de fleste af følgende symptomer: ondt i 
halsen, løbende næse, tilstoppet næse, nysen, hoste, hovedpine. </p>
<p>Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 patienter) 
 
følelse af trykken eller smerte i kinderne og panden (bihulebetændelse) 
 
løbende næse 
 
hoste 
 
ondt i halsen 
 
hovedpine 
 
svimmelhed 
 
hjertebanken 
 
muskelkramper 
 
hævede hænder, ankler og fødder (ødem) 
 
kløe/udslæt 
 
brystsmerter 
 
Smerter i muskler, knogler eller led </p>
<p>Ikke almindelige bivirkninger (kan forekomme hos op til 1 ud af 100 patienter) 
 
hurtig puls 
 
snurrende/prikkende fornemmelse eller følelsesløshed 
 
muskelsmerter </p>
<p>Nogle patienter hoster engang imellem lige efter inhalation af medicinen. Hoste er et typisk symptom 
på KOL. Hvis du oplever hoste umiddelbart efter inhalation af medicinen, er der ikke grund til 
bekymring. Kontroller inhalatoren for at se, om kapslen er tom, og at du har taget hele dosis. Hvis 
kapslen er tom, er der ikke grund til bekymring. Hvis kapslen ikke er tom, skal du inhalere igen i 
henhold til brugsanvisningen. </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, apotekspersonalet eller sygeplejerske. Dette 
gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende 
kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store oslif"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store oslif"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. 
Brug ikke lægemidlet efter den udløbsdato, der står på pakningen og blisteren efter "EXP". 
Udløbsdatoen er den sidste dag i den nævnte måned. 
Må ikke opbevares ved temperaturer over 30 °C. 
Opbevares i den originale pakning for at beskytte mod fugt og må først trykkes ud lige før brug. 
Brug ikke lægemidlet, hvis du bemærker at pakningen er beskadiget eller viser tegn på at have været 
åbnet. 
Spørg på apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du 
ikke smide medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oslif Breezhaler indeholder:</p>
<ul>
<li>Hver Oslif Breezhaler 150 mikrogram kapsel indeholder 150 mikrogram indacaterol i form af 
indacaterolmaleat. Øvrige indholdsstoffer: lactose og kapslen er lavet af gelatine. </li>
<li>Hver Oslif Breezhaler 300 mikrogram kapsel indeholder 300 mikrogram indacaterol i form af 
indacaterolmaleat. Øvrige indholdsstoffer: lactose og kapslen er lavet af gelatine. </li>
</ul>
<p>Udseende og pakningsstørrelser 
Denne pakning indeholder en inhalator samt kapsler i blister. Kapslerne er gennemsigtige (farveløse) 
og indeholder et hvidt pulver. </p>
<p> 
Oslif Breezhaler 150 mikrogram kapsler har påtrykt en sort produktkode "IDL 150" over en 
sort bjælke og et sort virksomhedslogo (
) påtrykt under den sorte bjælke. 
 
Oslif Breezhaler 300 mikrogram kapsler har påtrykt en blå produktkode "IDL 300" over en blå 
bjælke og et blåt virksomhedslogo (
) påtrykt under den blå bjælke. </p>
<p>Følgende pakningsstørrelser er tilgængelige: 
Pakning med 10 kapsler og 1 inhalator. 
Pakning med 30 kapsler og 1 inhalator. 
Multipakning bestående af 2 pakninger (hver pakning indeholder 30 kapsler og 1 inhalator). 
Multipakning bestående af 3 pakninger (hver pakning indeholder 30 kapsler og 1 inhalator). 
Multipakning bestående af 30 pakninger (hver pakning indeholder 10 kapsler og 1 inhalator). </p>
<p>Ikke alle pakningsstørrelser eller styrker er nødvendigvis markedsført i dit land. </p>
<p>Indehaver af markedsføringstilladelsen 
Novartis Europharm Limited 
Vista Building 
Elm Park, Merrion Road 
Dublin 4 
Irland </p>
<p>Fremstiller 
Novartis Pharma GmbH 
Roonstraße D-90429 Nürnberg 
Tyskland </p>
<p>Novartis Farmacéutica SA 
Gran Via de les Corts Catalanes, 08013 Barcelona 
Spanien </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Novartis Pharma N.V. 
Tél/Tel: +32 2 246 16<br />
Lietuva 
SIA Novartis Baltics Lietuvos filialas 
Tel: +370 5 269 16<br />
България 
Novartis Bulgaria EOOD 
Тел.: +359 2 489 98<br />
Luxembourg/Luxemburg 
Novartis Pharma N.V. 
Tél/Tel: +32 2 246 16<br />
Česká republika 
Novartis s.r.o. 
Tel: +420 225 775<br />
Magyarország 
Novartis Hungária Kft. 
Tel.: +36 1 457 65 Danmark 
Novartis Healthcare A/S 
Tlf: +45 39 16 84<br />
Malta 
Novartis Pharma Services Inc. 
Tel: +356 2122 2 </p>
<p>Deutschland 
Novartis Pharma GmbH 
Tel: +49 911 273 0 </p>
<p>Nederland 
Novartis Pharma B.V. 
Tel: +31 88 04 52 Eesti 
SIA Novartis Baltics Eesti filiaal 
Tel: +372 66 30<br />
Norge 
Novartis Norge AS 
Tlf: +47 23 05 20 Ελλάδα 
Novartis (Hellas) A.E.B.E. 
Τηλ: +30 210 281 17<br />
Österreich 
Novartis Pharma GmbH 
Tel: +43 1 86 6España 
Ferrer Internacional, S.A. 
Tel: +34 93 600 37<br />
Polska 
Novartis Poland Sp. z o.o. 
Tel.: +48 22 375 4France 
Pierre Fabre Médicament 
Tél: +33 1 49 10 96<br />
Portugal 
Laboratório Medinfar - Produtos Farmacêuticos, 
S.A. 
Tel: +351 21 499 7 
Hrvatska 
Novartis Hrvatska d.o.o. 
Tel. +385 1 6274<br />
România 
Novartis Pharma Services Romania SRL 
Tel: +40 21 31299 Ireland 
Novartis Ireland Limited 
Tel: +353 1 260 12<br />
Slovenija 
Novartis Pharma Services Inc. 
Tel: +386 1 300 75 Ísland 
Vistor hf. 
Sími: +354 535 7 
Slovenská republika 
Novartis Slovakia s.r.o. 
Tel: +421 2 5542 5 
Italia 
Novartis Farma S.p.A. 
Tel: +39 02 96 54 1 
Suomi/Finland 
Novartis Finland Oy 
Puh/Tel: +358 (0)10 6133<br />
Κύπρος 
Novartis Pharma Services Inc. 
Τηλ: +357 22 690<br />
Sverige 
Novartis Sverige AB 
Tel: +46 8 732 32<br />
Latvija 
SIA Novartis Baltics 
Tel: +371 67 887<br />
United Kingdom (Northern Ireland) 
Novartis Ireland Limited 
Tel: +44 1276 698 </p>
<p>Denne indlægsseddel blev senest ændret </p>
<p>Andre informationskilder 
Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu </p>
<p>BRUGSANVISNING TIL OSLIF BREEZHALER-INHALATOR </p>
<p>Læs venligst den fulde anvisning for brug inden du bruger Oslif Breezhaler. </p>
<p>Læg en kapsel i 
Perforer og slip 
Inhaler dybt 
Tjek, at kapslen er tom </p>
<p>Trin 1a: 
Fjern hætten 
Trin 2a: 
Perforer kapslen én 
gang 
Hold inhalatoren lodret. 
Perforer kapslen ved 
samtidig at trykke begge 
sideknapper helt ind. 
Trin 3a: 
Tag en dyb udånding 
Du må ikke puste i 
mundstykket.<br />
Tjek, at kapslen er tom 
Åben inhalatoren for at 
kontrollere, om der er 
overskydende pulver i 
kapslen. </p>
<p>Du vil høre et klik, når 
kapslen perforeres. 
Perforer kun kapslen én 
gang. </p>
<p>Hvis der er overskydende 
pulver i kapslen: 
 Luk inhalatoren. 
 Gentag trin 3a til 3c. 
Trin 1b: 
Åbn inhalatoren </p>
<p>Trin 2b: 
Slip sideknapperne helt<br />
Trin 3b: 
Inhaler medicinen dybt 
Hold inhalatoren som 
vist på billedet. Tag 
mundstykket i munden, 
og luk læberne tæt 
omkring det. Tryk ikke 
på sideknapperne. </p>
<p>Overskydende 
Tom 
pulver 
1 
2 
3 
Tjek </p>
<p>Tag en hurtig og så dyb 
indånding som muligt. 
Under inhalationen vil du 
høre en snurrende lyd. 
Du kan muligvis smage 
medicinen mens du 
inhalerer. </p>
<p>Trin 1c: 
Fjern kapslen 
Tryk en kapsel ud fra 
blisterkortet. 
Kapslen må ikke synkes. </p>
<p>Trin 3c: 
Hold vejret 
Hold vejret i op til 
5 sekunder. 
Fjern den tomme kapsel 
Smid kapslen ud sammen 
med almindeligt 
husholdningsaffald. Luk 
inhalatoren, og sæt hætten 
på igen. </p>
<p>Trin 1d: 
Læg kapslen i 
kapselkammeret 
Læg aldrig en kapsel 
direkte i mundstykket. </p>
<p>Vigtig information 
 Oslif Breezhaler kapsler 
skal altid opbevares i 
den originale blister og 
må først tages ud 
umiddelbart inden 
anvendelse. 
 Kapslerne må ikke 
synkes. 
 Brug ikke Oslif 
Breezhaler kapsler med 
nogen anden inhalator. 
 Brug ikke Oslif 
Breezhaler inhalatoren 
til at tage anden kapsel-
medicin. 
 Læg aldrig kapslen 
direkte i munden eller i 
inhalatorens 
mundstykke. 
 Tryk ikke på 
sideknapperne mere end 
én gang. 
 Pust ikke ind i 
mundstykket. 
 Tryk ikke på 
sideknapperne mens du 
inhalerer gennem 
mundstykket. 
 Håndter ikke kapslerne 
med fugtige hænder. 
 Vask aldrig din inhalator 
med vand. </p>
<p>Din Oslif Breezhaler inhalatorpakning indeholder: 
 
En Oslif Breezhaler inhalator 
 
Et eller flere blisterkort, som hver indeholder 
enten 6 eller 10 Oslif Breezhaler kapsler til brug 
i inhalatoren </p>
<p>Ofte stillede spørgsmål </p>
<p>Hvorfor lavede 
inhalatoren ikke en lyd, 
da jeg inhalerede? 
Kapslen kan muligvis 
sidde fast i kammeret. 
Hvis dette er tilfældet, skal 
du forsigtigt løsne kapslen 
ved at banke let på 
kapslens underdel. Inhaler 
medicinen igen ved at 
gentage trin 3a til 3c. </p>
<p>Hvad skal jeg gøre, hvis 
der er overskydende 
pulver i kapslen? 
Du har ikke fået en 
tilstrækkeligt mængde af 
din medicin. Luk 
inhalatoren og gentag 
trin 3a til 3c. </p>
<p>Jeg hostede efter jeg 
inhalerede - betyder det 
noget? 
Dette kan forekomme. Så 
længe kaplsen er tom, har 
du fået tilstrækkelig 
mængde af din medicin. </p>
<p>Jeg kunne mærke små 
stykker af kapslen på 
min tunge - betyder det 
noget? 
Dette kan forekomme, og 
det er ikke farligt. 
Risikoen for at kapslen går 
i små stykker forøges, hvis 
kapslen perforeres mere 
end én gang. 
Rengøring af inhalatoren 
Tør inderside og yderside 
af mundstykket med en 
ren, tør og fnugfri klud for 
at fjerne eventuelle 
pulverrester. Hold 
inhalatoren tør. Vask 
aldrig din inhalator med 
vand. 
Bortskaffelse af inhalator 
efter brug 
Hver inhalator skal 
bortskaffes efter alle 
kapslerne er brugt. Spørg 
på apoteket hvordan du 
skal bortskaffe medicin og 
inhalatorer, som du ikke 
længere har behov for. </p>
<p>Hætte 
Kapselkammer 
Underdel 
Mundstykke 
Gitter 
Blister 
Sideknapper 
Inhalator 
Inhalatorunderdel 
Blisterkort </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-69ba7123d300a992a466115b331a7218
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for oslif Package Leaflet for language en"
Description: "ePI document Bundle for oslif Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-69ba7123d300a992a466115b331a7218"
* entry[0].resource = composition-en-69ba7123d300a992a466115b331a7218

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp69ba7123d300a992a466115b331a7218"
* entry[=].resource = mp69ba7123d300a992a466115b331a7218
                            
                    
Instance: bundlepackageleaflet-da-69ba7123d300a992a466115b331a7218
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for oslif Package Leaflet for language da"
Description: "ePI document Bundle for oslif Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-69ba7123d300a992a466115b331a7218"
* entry[0].resource = composition-da-69ba7123d300a992a466115b331a7218

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp69ba7123d300a992a466115b331a7218"
* entry[=].resource = mp69ba7123d300a992a466115b331a7218
                            
                    



Instance: mp69ba7123d300a992a466115b331a7218
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Oslif Breezhaler 150 microgram inhalation powder, hard capsules"
Description: "Oslif Breezhaler 150 microgram inhalation powder, hard capsules"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/09/586/001-005"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Oslif Breezhaler 150 microgram inhalation powder, hard capsules"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 69ba7123d300a992a466115b331a7218ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "oslif"

* status = #current
* mode = #working

* title = "List of all ePIs associated with oslif"

* subject = Reference(mp69ba7123d300a992a466115b331a7218)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#oslif "oslif"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-69ba7123d300a992a466115b331a7218) // oslif en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-69ba7123d300a992a466115b331a7218) // oslif da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-69ba7123d300a992a466115b331a7218
InstanceOf: List

* insert 69ba7123d300a992a466115b331a7218ListRuleset
    